文献速递造血干细胞移植与细胞治疗

急性GVHD第28天治疗反应标准的细化:JSTCT与MAGIC协作研究

Refinement of day 28 treatment response criteria for acute GVHD: a collaboration study of the JSTCT and MAGIC.
PubMed 文献 · Blood Adv · 2025-01-01

该研究基于日本造血细胞移植与细胞治疗学会(JSTCT)初治队列,随机分为训练集与验证集,用分类回归树算法生成第28天细化反应(RR)标准,并在JSTCT与MAGIC验证集中评估其预测6个月非复发死亡的表现。RR在初治中AUC高于常规总反应(OR),在二线治疗中阴性预测值(NPV)明显高于OR。

要点

  • 第28天细化反应(RR)将无额外治疗且分级0/1者定义为反应者。
  • 初治验证中RR的AUC高于OR:JSTCT 0.73 vs 0.69,MAGIC 0.71 vs 0.68。
  • 二线治疗中RR的NPV高于OR:JSTCT 74.5% vs 66.0%,MAGIC 86.8% vs 76.1%。

核心结论

  • 外部验证的第28天细化反应(RR)可作为未来初治和二线治疗试验中优于常规标准的终点。

研究设计与样本

  • JSTCT初治队列患者被随机分为训练集和验证集,训练集用分类回归树算法基于治疗时和第28天症状生成第28天细化反应(RR)标准。
  • 在JSTCT和MAGIC验证集中,以6个月非复发死亡的AUC和NPV为性能指标评估RR。

主要发现

  • 初治验证中RR的AUC高于OR:JSTCT 0.73 vs 0.69(P < .001),MAGIC 0.71 vs 0.68(P = .032)。
  • 初治验证中RR的NPV略高于OR:JSTCT 92.0% vs 89.6%(P < .001),MAGIC 90.9% vs 89.8%(P = .009)。
  • 二线治疗验证中RR与OR的AUC相似:JSTCT 0.64 vs 0.63(P = .775),MAGIC 0.67 vs 0.64(P = .105)。
  • 二线治疗验证中RR的NPV高于OR:JSTCT 74.5% vs 66.0%(P < .001),MAGIC 86.8% vs 76.1%(P = .004)。
  • 将持续性但轻微的皮肤症状归为反应、将残留下消化道GVHD归为非反应,是改善RR预后表现的主要驱动因素。

关键数值与推荐

  • RR将第28天分级0/1且无额外治疗的患者定义为反应者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Overall response (OR) that combines complete (CR) and partial responses (PR) is the conventional end point for acute graft-versus-host disease (GVHD) trials. Because PR includes heterogeneous clinical presentations, reclassifying PR could produce a better end point. Patients in the primary treatment cohort from the Japanese Society for Transplantation and Cellular Therapy (JSTCT) were randomly divided into training and validation sets. In the training set, a classification and regression tree algorithm generated day 28 refined response (RR) criteria based on symptoms at treatment and day 28. We then evaluated RR for primary and second-line treatments, using the area under the receiver operating characteristic curve (AUC) and negative predictive value (NPV) for 6-month nonrelapse mortality as performance measures. RR considered patients with grade 0/1 at day 28 without additional treatment as responders. RR for primary treatment produced higher AUCs than OR with small improvement of NPVs in both validation sets: JSTCT (AUC, 0.73 vs 0.69 [P < .001]; NPV, 92.0% vs 89.6% [P < .001]) and the Mount Sinai Acute GVHD International Consortium (MAGIC; AUC, 0.71 vs 0.68 [P = .032]; NPV, 90.9% vs 89.8% [P = .009]). RR for second-line treatment produced similar AUCs but much higher NPVs than OR in both validation sets of JSTCT (AUC, 0.64 vs 0.63 [P = .775]; NPV, 74.5% vs 66.0% [P < .001]) and MAGIC (AUC, 0.67 vs 0.64 [P = .105]; NPV, 86.8% vs 76.1% [P = .004]). Classifying persistent but mild skin symptoms as responses and residual lower gastrointestinal GVHD as nonresponses were major drivers in improving the prognostic performance of RR. Our externally validated day 28 RR would serve as a better end point than conventional criteria in future first- and second-line treatment trials.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Akahoshi Y, Inamoto Y, Spyrou N, et al. Refinement of day 28 treatment response criteria for acute GVHD: a collaboration study of the JSTCT and MAGIC. Blood Adv. 2025. PMID: 40590886. doi:10.1182/bloodadvances.2025016233

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。